2012 Pharmaceuticals Research Review

Published by: BCC Research

Published: Dec. 1, 2012 - 129 Pages

Table of Contents

CHAPTER 1 FOREWORD

CHAPTER 2 GLOBAL MARKETS FOR TREATMENTS FOR SYNDROMES OF PROGRESSIVE

ATAXIA AND WEAKNESS DISORDERS (REPORT PHM118A)

INTRODUCTION

STUDY OBJECTIVES

REASONS FOR DOING THIS STUDY

CONTRIBUTIONS OF THE STUDY AND FOR WHOM

SCOPE OF THE STUDY

METHODOLOGY

INFORMATION SOURCES

ABOUT THE AUTHOR

RELATED BCC RESEARCH REPORTS

EXECUTIVE SUMMARY

TABLE 1 GLOBAL MARKET FOR PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS, THROUGH 2017 ($ MILLIONS)

FIGURE 1 GLOBAL MARKET FOR PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS, 2010–2017 ($ MILLIONS)

OVERVIEW

DEFINITIONS

NEURONS

CENTRAL NERVOUS SYSTEM

BRAIN

SPINAL CORD

NEUROTRANSMITTERS

CLASSIFICATION

TABLE 2 CLASSIFICATION BY PRIMARY DYSFUNCTION

PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS

FRIEDREICH'S ATAXIA

GERSTMANN-STRAUSSLER-SCHEINKER DISEASE

MACHADO-JOSEPH DISEASE

AMYOTROPHIC LATERAL SCLEROSIS

HEREDITARY SPASTIC PARAPLEGIA

HEREDITARY NEUROPATHIES

MULTIPLE SCLEROSIS

DIAGNOSTIC TESTS FOR PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS

DIAGNOSTIC TESTS FOR MULTIPLE SCLEROSIS

DIAGNOSTIC TESTS FOR AMYOTROPHIC LATERAL SCLEROSIS

DIAGNOSTIC TESTS FOR FRIEDREICH'S ATAXIA

DIAGNOSTIC TESTS FOR MACHADO-JOSEPH DISEASE

DIAGNOSTIC TESTS FOR HEREDITARY SPASTIC PARAPLEGIA

DIAGNOSTIC TESTS FOR HEREDITARY NEUROPATHIES

GLOBAL MARKETS

MARKETS BY DYSFUNCTION

MARKET OVERVIEW

MARKET REVENUE

TOPIC

TABLE 3 GLOBAL REVENUES OF DRUG PRODUCTS FOR THE TREATMENT OF NEURODEGENERATIVE DYSFUNCTIONS, THROUGH 2017 ($ MILLIONS)

FIGURE 2 GLOBAL REVENUES OF DRUG PRODUCT FOR THE TREATMENT OF NEURODEGENERATIVE DYSFUNCTIONS, 2010–2017 ($ MILLIONS)

MARKET SHARE

TABLE 4 MARKET SHARE OF DRUGS USED FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS BY DYSFUNCTIONS, 2011 (%)

FIGURE 3 MARKET SHARE OF DRUG USED FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS BY DYSFUNCTION, 2011 (%)

MARKETS BY DISORDERS

MARKET OVERVIEW

CURRENT SITUATION

MARKET TRENDS

PROGRESSIVE ATAXIAS SYNDROMES

Market Drivers

PROGRESSIVE WEAKNESS AND EFFECT IN THE BRAIN AND SPINAL CORD

SYNDROMES

Market Drivers

ADDITIONAL DRIVERS FOR PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS DRUG

MARKET

FACTORS GOVERNING THE MARKET

COLLABORATIONS, MERGERS AND ACQUISITIONS

CHAPTER 3 ANTIFUNGAL DRUGS: TECHNOLOGIES AND GLOBAL MARKETS (REPORT PHM029D)

INTRODUCTION

STUDY GOALS AND OBJECTIVES

REASONS FOR DOING THIS STUDY

INTENDED AUDIENCE

SCOPE OF REPORT

METHODOLOGY

INFORMATION SOURCES

ANALYST CREDENTIALS

RELATED BCC REPORTS

SUMMARY

TABLE 5 GLOBAL MARKET FORECAST FOR HUMAN ANTIFUNGAL THERAPEUTICS BY GEOGRAPHIC REGION, THROUGH 2016 ($ MILLIONS)

FIGURE 4 GLOBAL SALES OF HUMAN ANTIFUNGALS, 2011 AND 2016 ($ MILLIONS)

OVERVIEW

HISTORY AND CURRENT STATE OF ANTIFUNGALS

TYPES OF PATHOGENIC FUNGI

DEFINITION OF THE INDUSTRY

INDUSTRY CONCEPTS

IMPORTANCE OF THE INDUSTRY

PRODUCT LIFE CYCLES

TABLE 6 DRUG DEVELOPMENT LIFECYCLE FOLLOWING DISCOVERY OF NEW DRUG

DEVELOPMENT OF ANTIFUNGALS

FDA-APPROVED ANTIFUNGALS

AZOLE ANTIFUNGALS

ECHINOCANDINS

POLYENES

ALLYLAMINES

MISCELLANEOUS ANTIFUNGALS

FUTURE DEVELOPMENTS

HUMAN CLINICAL DEVELOPMENT, 2009 TO 2011

NEW DRUG ACTIVITY

TABLE 7 CLINICAL TRIALS OF ALL NEW DRUG THERAPIES AND COMBINATIONS BY ALL DATE FIELDS, 2009–2011

TABLE 8 SELECTED GLOBAL CLINICAL TRIALS OF ALL NEW DRUG THERAPIES THAT EITHER ARE COMPLETED OR ESTIMATED TO BE COMPLETED BETWEEN 2009 AND 2012

ACTIVE OR COMPLETED STUDIES POSTED OR UPDATED, 2009 TO 2011

TABLE 9 ACTIVE OR COMPLETED STUDIES, 2009–2011

INTRODUCTION TO INDUSTRY APPLICATIONS OF ANTIFUNGAL MEDICINAL

THERAPEUTICS

SCOPE OF APPLICATIONS: HUMAN HEALTHCARE

HUMAN FUNGAL INFECTIONS

Risk Factors for Developing Fungal Infections

TABLE 10 RISK FACTORS ASSOCIATED WITH HUMAN FUNGAL INFECTIONS

CHAPTER 4 GLOBAL MARKETS FOR ASTHMA AND COPD DRUGS (REPORT PHM059B)

INTRODUCTION

STUDY GOALS AND OBJECTIVES

REASONS FOR DOING THE STUDY

SCOPE OF REPORT

METHODOLOGY

INTENDED AUDIENCE

INFORMATION SOURCES

ANALYST CREDENTIALS

RELATED BCC REPORTS

SUMMARY

TABLE 11 GLOBAL MARKET FOR ASTHMA AND COPD PRESCRIPTION DRUGS BY DISEASE, THROUGH 2017 ($ MILLIONS)

FIGURE 5 GLOBAL MARKET FOR ASTHMA AND COPD PRESCRIPTION DRUGS BY REGION, 2012 AND 2017 (%)

OVERVIEW

PULMONARY DRUG DELIVERY

PULMONARY CONDITIONS AND THERAPIES

RESPIRATORY SYSTEM

LUNG

Particle Size, Toxicity and Drug Deposition

Systemic and Local Therapy

Pulmonary Drug Delivery-Devices

Device Characteristics

Manufacturing Techniques

ASTHMA

Symptoms of Asthma

Global Prevalence

CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Symptoms of COPD

Medication Treatment

Types of Medication Treatments

Classification of Asthma and COPD Medications

Bronchodilators

Quick-acting Bronchodilators

Two Classes of Long-Term Bronchodilators

Anti-inflammatory Drugs

Combination Inhaled Corticosteroids and Long-acting Beta-2 Agonists (ICS/LABA)

Advantages of ICS/LABA

TABLE 12 MARKETED ASTHMA AND COPD DRUG CLASSES

Drug Delivery Methods

Inhaled Drugs

Metered-dose Inhaler

Pressurized MDI Devices

Types of Metered-dose Inhalers

Breath-activated Inhalers

Types of Breath-activated Inhalers

Dry Powder Inhalers

Disadvantages of DPI

Types of DPI Inhalers

Nebulizers

Usage

Types of Nebulized Drugs

Oral and Injectable Drugs

Oral Drug Types

Injectable Drug Types

ADVANTAGES/DISADVANTAGES OF DRUG DELIVERY METHODS

DRUG DEVELOPMENT PROCESS

DEVELOPMENT OF DISEASE-MODIFYING DRUGS

New Drug Targets

TECHNICAL ASPECTS IN THE DEVELOPMENT OF INHALED DRUGS

INTELLECTUAL PROPERTY RIGHTS

DRUG DEVELOPMENT

COMPLEX REGULATORY DRUG APPROVAL PROCESS

Approval Times

REGULATORY ISSUES

REMOVAL OF CFC-PROPELLED INHALERS

FDA DRUG SAFETY WARNINGS

INDUSTRY PLAYERS

TIERS OF COMPETITION

MAJOR DRUG MANUFACTURERS

GlaxoSmithKline

Merck

Boehringer Ingelheim

TABLE 13 NET REVENUES FOR TOP SIX ASTHMA/COPD PRODUCT MANUFACTURERS, WITH PRODUCT(S), 2010 AND 2011 ($ MILLIONS)

SPECIALTY PHARMACEUTICAL COMPANIES

Teva Pharmaceutical

Chiesi Farmaceutici

Sunovion/Sepracor

TABLE 14 NET REVENUES FOR TOP SPECIALTY ASTHMA/COPD MANUFACTURERS WITH PRODUCT(S), 2010 AND 2011 ($ MILLIONS)

SMALLER COMPANIES

TABLE 15 NET REVENUES FOR SMALLER ASTHMA/COPD PRODUCT MANUFACTURER, WITH PRODUCT, 2010 AND 2011 ($ MILLIONS)

ACQUISITIONS AND MERGERS

TABLE 16 ACQUISITIONS AND MERGERS IN THE ASTHMA AND COPD MARKET, JAN. 2008 TO JUNE 2012 ($ MILLIONS)

COMPETITIVE FACTORS

SIX COMPETITIVE FACTORS

Delivery Mode and Convenience

Product Efficacy and Dosage Frequency

Safety

Combination Drugs

Drug Pricing

Sales and Marketing

SIGNIFICANT TRENDS

GLOBAL AGING POPULATION LEADS TO INCREASING ASTHMA AND COPD

PREVALENCE

NEW DRUG LAUNCHES OFFER ENHANCED TREATMENT OPTIONS

PATENT EXPIRATIONS OF MAJOR DRUGS AND GENERIC DRUG LAUNCHES WILL

CHANGE THE MARKET

CHAPTER 5 GENITOURINARY DRUGS: TECHNOLOGIES AND GLOBAL MARKETS (REPORT PHM115A)

INTRODUCTION

STUDY GOALS AND OBJECTIVES

REASONS FOR DOING THE STUDY

SCOPE OF REPORT

INTENDED AUDIENCE

METHODOLOGY AND INFORMATION SOURCES

ANALYST CREDENTIALS

RELATED BCC REPORTS

SUMMARY

TABLE 17 MAJOR GENITOURINARY DRUG CATEGORIES REVENUE, THROUGH 2016 ($ MILLIONS)*

FIGURE 6 MAJOR GENITOURINARY DRUG CATEGORIES REVENUE, 2009-2016 ($ MILLIONS)*

OVERVIEW

DISEASES OF THE GENITOURINARY SYSTEM

TABLE 18 GENITOURINARY DISEASE NAMES, GENDER AND DESCRIPTION

Benign Prostatic Hypertrophy (BPH)

Erectile Dysfunction (ED)

Incontinence (IC)

Overactive Bladder (OB)

Hormonal Contraception (HC)

Infertility (IF)

Infection (INF)

DRUGS GOING OFF-PATENT IN FORECAST PERIOD

TABLE 19 GENITOURINARY DRUGS WITH EXPIRING PATENTS, 2010–2016

REVENUE PROJECTION FOR GENITOURINARY DRUGS, 2011-2016

TABLE 20 FIVE-YEAR PROJECTION FOR REVENUES IN GENITOURINARY DRUG MARKET, THROUGH 2016 ($ MILLIONS)

TOP 10 BEST-SELLING GENITOURINARY DRUGS, 2011

TABLE 21 TOP 10 BEST-SELLING GENITOURINARY DRUGS IN 2011 ($ MILLIONS/%)

REVENUE BY GENITOURINARY DISEASE DRUG SEGMENT

TABLE 22 REVENUES BY GENITOURINARY SEGMENT, 2011 ($ MILLIONS/%)

REVENUE FROM GENITOURINARY DRUGS BY GEOGRAPHIC AREA

TABLE 23 REVENUE FROM GENITOURINARY DRUGS BY GEOGRAPHIC AREA, 2011 ($ MILLIONS/%)

MARKET OVERVIEW

MARKET SIZE AND FORECAST

TABLE 24 REVENUE FROM GENITOURINARY DISEASE DRUGS FOR MAJOR COMPANIES, THROUGH 2016 ($ MILLIONS)

CHAPTER 6 GLOBAL MARKETS FOR TREATMENTS FOR SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS (REPORT PHM117A)

INTRODUCTION

STUDY OBJECTIVES

REASONS FOR DOING THIS STUDY

CONTRIBUTIONS OF THE STUDY AND FOR WHOM

SCOPE OF THE STUDY

METHODOLOGY

INFORMATION SOURCES

ABOUT THE AUTHOR

RELATED BCC RESEARCH REPORTS

EXECUTIVE SUMMARY

TABLE 25 GLOBAL MARKET FOR TREATMENTS FOR SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, THROUGH 2017 ($ MILLIONS)

FIGURE 7 GLOBAL MARKET FOR TREATMENTS FOR SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, 2010–2017 ($ MILLIONS)

OVERVIEW

THE BRAIN

CEREBRAL CORTEX

BRAIN STEM

SPINAL CORD

NEUROTRANSMITTERS

CLASSIFICATION OF NEURODEGENERATIVE DISORDERS

TABLE 26 CLASSIFICATION OF SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY PRIMARY CLINICAL/PATHOLOGICAL FEATURE

NEURODEGENERATIVE DISORDERS

ALZHEIMER'S DISEASE

LEWY BODY DEMENTIA

PICK'S DISEASE

HUNTINGTON'S DISEASE

CORTICAL BASAL GANGLIONIC DEGENERATION

PARKINSON'S DISEASE

MULTIPLE SYSTEM ATROPHY

PROGRESSIVE SUPRANUCLEAR PALSY

HALLERVORDEN-SPATZ DISEASE

DIAGNOSTIC TESTS FOR NEURODEGENERATIVE DISORDERS

DIAGNOSTIC TESTS FOR PARKINSON'S

DIAGNOSTIC TESTS FOR ALZHEIMER'S

DIAGNOSTIC TESTS FOR PICK'S DISEASE

DIAGNOSTIC TESTS FOR MULTIPLE SYSTEM ATROPHY

DIAGNOSTIC TESTS FOR PROGRESSIVE SUPRANUCLEAR PALSY

DIAGNOSTIC TESTS FOR CORTICAL BASAL GANGLIONIC DEGENERATION

DIAGNOSTIC TESTS FOR LEWY BODY DEMENTIA

DIAGNOSTIC TESTS FOR HALLERVORDEN-SPATZ DISEASE

GLOBAL MARKETS

MARKETS BY CLINICAL/PATHOLOGICAL FEATURE

Market Overview

Market Revenues

TABLE 27 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, THROUGH 2017 ($ MILLIONS)

FIGURE 8 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, 2010–2017 ($ MILLIONS)

Market Share

TABLE 28 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT NEURODEGENERATIVE DISORDERS BY CLINICAL/PATHOLOGICAL FEATURE, 2011 (%)

FIGURE 9 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT NEURODEGENERATIVE DISORDERS BY CLINICAL/PATHOLOGICAL FEATURE, 2011 (%)

MARKET BY DISEASE TYPE

Market Overview

CURRENT SITUATION

MARKET TRENDS

SYNDROMES OF DEMENTIA

Market Drivers

MOVEMENT DISORDER SYNDROMES

Market Drivers

OVERALL DRIVERS OF THE MARKET FOR TREATMENTS FOR SYNDROMES OF DEMENTIA

AND MOVEMENT DISORDERS

OTHER FACTORS AFFECTING THE MARKET

COLLABORATIONS/MERGERS AND ACQUISITIONS

Abstract

This review of pharmaceutical market research provides:

Analysis and the future direction of treatments for neurodegenerative (i.e., progressive ataxia and weakness) disorders as the market efforts toward drug and therapy development evolve.

Coverage of approved human antifungal therapeutics with a heavy focus on therapeutics in early development.

Profiles of manufacturers of leading asthma and chronic obstructive pulmonary disease (COPD) prescription drugs.

Comprehensive analysis of the market for genitourinary drugs on a global basis.

Current and future characteristics of the global markets for treatments for syndromes of dementia and movement disorders.

Get full details about this report >>

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports, company profiles and country profiles from over 720 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.